Sales and Earnings Projections

Corporate earnings can be a key driver in the movement of stock prices. The Navellier stock selection methodology has long focused on identifying those stocks with the capacity for strong earnings growth. In many instances the stocks that we select beat analyst expectations. Thus, should such “earnings surprises” occur, it can be a major positive event for the price action in the stock.

Sales And Earnings Projections as of 5/17/2019
Ticker Company Name Price Next
VEEV Veeva Systems Inc 141.76 22.1% 35.2% 11.8%
CMG Chipotle Mexican Grill Inc 715.91 10.7% 29.6% 12.8%
NOW Servicenow Inc 272.99 31.9% 28.4% 23.7%
LULU Lululemon Athletica Inc 173 16.3% 28.3% 6.2%
XLNX Xilinx Inc 104.76 23.9% 26.3% 0.8%
TEAM Atlassian Corp Plc 129.15 35.6% 22.7% 13.7%
FTNT Fortinet Inc 82.62 15.9% 22.3% 19.1%
PYPL Paypal Holdings Inc 112.8 12.3% 19.6% 15.3%
CPRT Copart Inc 65.6 12.0% 19.2% 2.7%
KEYS Keysight Technologies Inc 81.86 7.5% 18.6% 16.0%
CDNS Cadence Design Systems Inc 68.66 11.8% 18.3% 9.9%
ANET Arista Networks Inc 250.12 16.8% 13.9% 11.6%
AZO Autozone Inc 984.09 4.2% 12.8% 15.4%
UBNT Ubiquiti Networks Inc 128.08 11.3% 12.3% 14.5%
HEI Heico Corp 103.14 11.3% 11.5% 24.2%
MA Mastercard Inc 252.55 11.4% 10.2% 7.2%
UNH Unitedhealth Group Inc 241.38 7.9% 10.0% 3.7%
ORLY O'reilly Automotive Inc 353.02 6.4% 9.3% 0.1%
VRSN Verisign Inc 195.3 1.4% 9.1% 4.8%
TWTR Twitter Inc 37.5 16.5% 8.9% 141.0%
AMZN Inc 1869 18.1% 8.7% 50.5%
WEX Wex Inc 201.91 18.8% 8.5% 2.0%
ADBE Adobe Inc 279.85 23.2% 7.3% 5.8%
OKE Oneok Inc 68.17 2.7% 6.5% 10.4%
LW Lamb Weston Holdings Inc 67.63 6.0% 5.6% 14.7%
ZTS Zoetis Inc 101.97 7.2% 5.5% 11.6%
SPGI S&p Global Inc 212.94 2.7% 5.1% -0.5%
ISRG Intuitive Surgical Inc 490.14 13.6% 3.8% -3.3%
VMW Vmware Inc -cl A 203.64 11.8% 1.2% 5.5%
ROST Ross Stores Inc 97.2 5.7% 1.0% 6.4%
VRSK Verisk Analytics Inc 141.97 6.9% 0.7% -0.4%
BURL Burlington Stores Inc 165.25 6.5% -0.5% 2.2%
CME Cme Group Inc 183.85 12.3% -8.0% 1.5%
BA Boeing Co 355.02 -18.9% -46.7% -1.0%
DXCM Dexcom Inc 118.04 25.9% -100.7% 65.4%
NBIX Neurocrine Biosciences Inc 79.03 68.7% -262.9% -43.1%

Although the information in this communication is believed to be materially correct, no representation or warranty, express or implied, is given as to the accuracy of any of the information provided. Certain information included in this communication is based on information obtained from sources considered to be reliable. However, any projections or analysis provided to assist the recipient of this communication in evaluating the matters described herein may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results. Accordingly, any projections or analysis should not be viewed as factual and should not be relied upon as an accurate prediction of future results. Furthermore, to the extent permitted by law, neither Navellier & Associates, Inc. (“Navellier”), nor any of its affiliates, agents, or service providers assumes any liability or responsibility nor owes any duty of care for any consequences of any person acting or refraining to act in reliance on the information contained in this communication or for any decision based on it. This communication is not intended to constitute, and should not be construed as, investment advice. Potential investors in any Navellier investment products should seek their own independent financial advice. Navellier does not provide investment advice. This communication has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any Navellier investment strategy or composites. This communication is not intended as and is not to be taken as an offer or solicitation with respect to the purchase or sale of any security or interest, nor does it constitute an offer or solicitation in any jurisdiction, including those in which such an offer or solicitation is not authorised or to any person to whom it is unlawful to make such a solicitation or offer.

Potential investors should consult with their financial advisor before investing in any Navellier Investment Product.

It should not be assumed that any securities recommendations made by Navellier & Associates, Inc., in the future will be profitable or equal the performance of securities made in this report.

Investment in equity strategies is speculative in nature and involves substantial risk, including the potential for partial or complete loss of funds invested.

Navellier claims compliance with Global Investment Performance Standards (GIPS). To receive a complete list and descriptions of Navellier's composites and/or a presentation that adheres to the GIPS standards, please contact Navellier or click here. It should not be assumed that any securities recommendations made by Navellier & Associates, Inc. in the future will be profitable or equal the performance of securities made in this report. Request here a list of recommendations made by Navellier & Associates, Inc. for the preceding twelve months.